<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190730044382N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-05-02</date_registration>
      <primary_sponsor>Gonabad University of Medical Sciences</primary_sponsor>
      <public_title>Effect of oral vitamin B6 on common complaints of first trimester pregnancy</public_title>
      <acronym></acronym>
      <scientific_title>Effect of oral vitamin B6 on common complaints of first trimester pregnancy in women referred to community health centers in Gonabad in 2019-2020</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-03-05</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>72</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/45743</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: For sampling, each person will be selected for inclusion in the study, and then the samples will be divided into two intervention groups (A (or control) B) based on 4-block design and random allocation. A 4-block block will be used for sampling (AABB, ABAB, BBAA, BABA), Blinding description: In this study vitamin B6 and placebo will be prepared in packages including 30 tablets as A and B. Due to the method of the study, the research unit and the researcher have no information about each package; it means that placebo (manufactured by Mashhad School of Pharmacy) and vitamin B6 tablets is provided in A and B packages that are completely similar. These packages are prepared by another person (not the researcher) then are given to the researcher. After explaining phases of the research to the research units and obtaining written consent will be placed in two groups of intervention and control based on random block allocation. 4-block packages will be used for sampling (AABB, ABAB, BBAA, BABA).</study_design>
      <phase>3</phase>
      <hc_freetext>Common complaints in the first trimester of pregnancy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Oral vitamin B6 tablet 40 mg, daily for 30 days Manufactured by Iran Hormone Company. Intervention 2: Control group: One  40 mg tablet containingstarch daily for 30 days, manufactured by Mashhad School of Pharmacy.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Asma Salar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam Khomeiny</address>
        <city>Gonabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۹۶۹۱۷۹۳۷۱۸</zip>
        <telephone>+98 51 5722 2598</telephone>
        <email>asmasalar69@gmail.com</email>
        <affiliation>Gonabad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Asma Salar</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Emam Khomeiny</address>
        <city>Gonabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>۹۶۹۱۷۹۳۷۱۸</zip>
        <telephone>+98 51 5722 2598</telephone>
        <email>asmasalar69@gmail.com</email>
        <affiliation>Gonabad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Age 18-40 years
Pregnancy age 6-10 weeks
Low risk pregnancy
Depression score less than 12
Lack of physical and mental illness
Use supplements the first trimester of pregnancy (iodopholic and vitamin D3)
No breastfeeding
Knowing how to read and write
Hemoglobin greater than 11 gr/d
Breast pain with pregnancy starting for 5 days or more
Pregnancy wanted
No history of stillbirth
No history recurrent abortion
No history of infertility
Do not used B6 supplementation before recent pregnancy
Normal body mass index (18.5-24.9)
No employment  in night shift
Sleep quality score of 5 or more
Fatigue score greater than one
Mild to moderate nausea and vomiting score (score 3-12)</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>40 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Not using vitamin B6 in intervention group
Not using placebo in control group
Abortion or medical termination of pregnancy
Unwillingness to participate in follow-up study.
Not filling questionnaires during  the study
Pregnancy twins or moles
Receiving new medication during the study.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Oral vitamin B6 tablet 40 mg, daily for 30 days Manufactured by Iran Hormone Company</i_keyword>
      <i_keyword>Control group: One  40 mg tablet containingstarch daily for 30 days, manufactured by Mashhad School of Pharmacy.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The effect of vitamin B6 on breast pain. Timepoint: Measurement of breast pain at the beginning and end of the study. Method of measurement: The Visual Analogue Scale Questionnaire is a standard instrument measuring a 10 cm ruler. Depending on the amount of pain, the person signs on the continuum for the past 48 hours. The Linear-Visual Measurement Scale of Pain is classified as 0 to 10 as follows: 0: No pain, 3-1: Mild pain, 4-6: Moderate pain, 10-7: Severe pain.</prim_outcome>
      <prim_outcome>The effect of vitamin B6 on depression score in pregnant women. Timepoint: At the beginning and end of the study. Method of measurement: The Edinburgh Depression Questionnaire is used to measure depression during pregnancy and postpartum. The tool has 10 four-choice questions and each question has a score of 0-3 and its overall score ranges from 0-30. In Iran, a score of 12 or higher is a sign of mothers' depression.</prim_outcome>
      <prim_outcome>The effect of vitamin B6 on sleep quality of pregnant women. Timepoint: At the beginning and end of the study. Method of measurement: Petersburg Sleep Quality Questionnaire (PSQI) One of the best tools designed to measure sleep quality is the Petersburg Sleep Quality Questionnaire (PSQI). The sum of the 7 subscale scores will be between 0 and 21. Getting a total score above 5 on the whole questionnaire means poor sleep quality.</prim_outcome>
      <prim_outcome>The effect of vitamin B6 on fatigue in pregnant women. Timepoint: At the beginning and end of the study. Method of measurement: Multidimensional Fatigue Scale (MAF) Questionnaire, which is used to measure fatigue and is capable of measuring fatigue in pregnant women.</prim_outcome>
      <prim_outcome>The effect of vitamin B6 on pregnancy nausea and vomiting. Timepoint: At the beginning and 4 days after the start of the study. Method of measurement: The 24-hour Pregnancy Nausea and Vomiting Questionnaire (PUQE-FORM-24) consisted of three questions that measured the duration of nausea, vomiting time, and frequency of frustration over the past 24 hours, with scores ranging between 15 and 3. Less than or equal to 6 indicates mild nausea and vomiting, moderate nausea and vomiting 7-12 and more or less than 13 severe forms.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Gonabad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-02-02</approval_date>
        <contact_name>Ethics committee of Gonabad University of Medical Sciences</contact_name>
        <contact_address>Asian Road Margin, Gonabad University of Medical Sciences Gonabad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
